Preprint
Brief Report

The Rational for Administration of ACE2 Pathway Inhibitors in Patients Infected by SARS-CoV-2: Devising an Administration Strategy

This version is not peer-reviewed.

Submitted:

23 March 2020

Posted:

24 March 2020

Read the latest preprint version here

A peer-reviewed article of this preprint also exists.

Abstract
The article describes the rational for inhibition of the angiotensin-converting enzyme 2 (ACE2) pathways as specific targets in patients infected by SARS-CoV-2. Making use of a large quantity of published reports in which human/rodent ACE2 pathway inhibitors were administered in vivo, I have hypothesized a possible therapeutic pharmacological intervention through an inhibition strategy of ACE2 pathway for SARS-CoV-2 patients who are suffering from critical, advanced and untreatable stages of the disease.
Keywords: 
Severe Acute Respiratory Syndrome Coronavirus-2; (soluble) ACE2; eosinophil; asthma; IL-10; IL-6; Lung fibrosis; Angiotensin; hypoxia; infarction; hypertension; hypercapnic acidosis; hypoxia; infarction; hypertension
Subject: 
Medicine and Pharmacology  -   Pathology and Pathobiology
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Downloads

1955

Views

1295

Comments

3

Subscription

Notify me about updates to this article or when a peer-reviewed version is published.

Email

Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

Subscribe

© 2025 MDPI (Basel, Switzerland) unless otherwise stated